Background: The aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (Fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naïve to antiretroviral treatment (ICONA). Methods: All patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology. Results: Patients who were HBcAb+/HCV-/HBs antigen (HBsAg)-and HCV+/HBcAb+/HBsAg-or HBsAg+/HBcAb+/HCV-had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P <. 0001). A Cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg-patients (HR, 7.2; 95% CI, 3 8-13.64). Conclusions: HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg-subjects. A careful monitoring for signs of previous HBV infection is needed in this kind of patients.

Malagnino, V., Cerva, C., Cingolani, A., Ceccherini-Silberstein, F., Vergori, A., Cuomo, G., et al. (2021). HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients. OPEN FORUM INFECTIOUS DISEASES, 8(1), 1-8 [10.1093/ofid/ofaa566].

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

Puoti M.;
2021

Abstract

Background: The aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (Fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naïve to antiretroviral treatment (ICONA). Methods: All patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology. Results: Patients who were HBcAb+/HCV-/HBs antigen (HBsAg)-and HCV+/HBcAb+/HBsAg-or HBsAg+/HBcAb+/HCV-had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P <. 0001). A Cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg-patients (HR, 7.2; 95% CI, 3 8-13.64). Conclusions: HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg-subjects. A careful monitoring for signs of previous HBV infection is needed in this kind of patients.
Articolo in rivista - Articolo scientifico
anti-HBc; HBV; HIV/HBV coinfection; liver fibrosis; OBI;
English
18-nov-2020
2021
8
1
1
8
none
Malagnino, V., Cerva, C., Cingolani, A., Ceccherini-Silberstein, F., Vergori, A., Cuomo, G., et al. (2021). HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients. OPEN FORUM INFECTIOUS DISEASES, 8(1), 1-8 [10.1093/ofid/ofaa566].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/304517
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
Social impact